Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model

References

• Cuypers J, Mathieu C, Benhalima K. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice. Acta Clin Belg. 2013;68(4):287–293. doi:10.2143/ACB.3349
   PubMed Web of Science ®Google Scholar
• Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53(5):875–883. doi:10.1053/j.ajkd.2008.12.031
   PubMed Web of Science ®Google Scholar
• Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139(11):1384–1395. doi:10.1161/CIRCULATIONAHA.118.037778
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi:10.1056/NEJMoa1611925
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi:10.1056/NEJMoa1812389
   PubMed Web of Science ®Google Scholar
• McMurray JJV, DeMets DL, Inzucchi SE, et al. The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail. 2019;21(11):1402–1411. doi:10.1002/ejhf.1548
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi:10.1056/NEJMoa2024816
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial. J Am Coll Cardiol. 2021;77(11):1381–1392. doi:10.1016/j.jacc.2021.01.033
   PubMed Web of Science ®Google Scholar
• Andreadou I, Efentakis P, Balafas E, et al. Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol. 2017;8:1077. doi:10.3389/fphys.2017.01077
   PubMed Web of Science ®Google Scholar
• Leng W, Ouyang X, Lei X, et al. The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(-/-) mice. Mediators Inflamm. 2016;2016:6305735. doi:10.1155/2016/6305735
   PubMed Web of Science ®Google Scholar
• Garcia-Ropero A, Santos-Gallego CG, Zafar MU, et al. Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opin Drug Metab Toxicol. 2019;15(4):275–285. doi:10.1080/17425255.2019.1588886
   PubMed Web of Science ®Google Scholar
• Lamacchia O, Sorrentino MR. Diabetes mellitus, arterial stiffness and cardiovascular disease: clinical implications and the influence of SGLT2i. Curr Vasc Pharmacol. 2020;19(2):233–240. doi:10.2174/1570161118666200317150359
   Web of Science ®Google Scholar
• Hidalgo Santiago JC, Maraver Delgado J, Cayon Blanco M, et al. Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus. Med Clin. 2020;154(5):171–174. doi:10.1016/j.medcli.2019.05.028
   PubMed Web of Science ®Google Scholar
• Al-Sharea A, Murphy AJ, Huggins LA, et al. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr(-/-) type 1 diabetic mice. Atherosclerosis. 2018;271:166–176. doi:10.1016/j.atherosclerosis.2018.02.028
   PubMed Web of Science ®Google Scholar
• Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6(7):508–519. doi:10.1038/nri1882
   PubMed Web of Science ®Google Scholar
• Wang C, Niimi M, Watanabe T, et al. Treatment of atherosclerosis by traditional Chinese medicine: questions and quandaries. Atherosclerosis. 2018;277:136–144. doi:10.1016/j.atherosclerosis.2018.08.039
   PubMed Web of Science ®Google Scholar
• Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:m4573. doi:10.1136/bmj.m4573
   PubMed Web of Science ®Google Scholar
• Li CX, Liang S, Gao L, et al. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS One. 2021;16(2):e0244689. doi:10.1371/journal.pone.0244689
   PubMed Web of Science ®Google Scholar
• Raggi P, Genest J, Giles JT, et al. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis. 2018;276:98–108. doi:10.1016/j.atherosclerosis.2018.07.014
   PubMed Web of Science ®Google Scholar
• Shah PK. Inflammation, infection and atherosclerosis. Trends Cardiovasc Med. 2019;29(8):468–472. doi:10.1016/j.tcm.2019.01.004
   PubMed Web of Science ®Google Scholar
• Prattichizzo F, De Nigris V, Micheloni S, et al. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component? Diabetes Obes Metab. 2018;20(11):2515–2522. doi:10.1111/dom.13488
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131. doi:10.1056/NEJMoa1707914
   PubMed Web of Science ®Google Scholar
• Lee SG, Lee SJ, Lee JJ, et al. Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2 (SGLT-2) inhibitor in a normoglycemic rabbit model. Korean Circ J. 2020;50(5):443–457. doi:10.4070/kcj.2019.0296
   PubMed Web of Science ®Google Scholar
• Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298–310. doi:10.1016/j.freeradbiomed.2017.01.035
   PubMed Web of Science ®Google Scholar
• Xu L, Nagata N, Nagashimada M, et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–149. doi:10.1016/j.ebiom.2017.05.028
   PubMed Web of Science ®Google Scholar
• Miyachi Y, Tsuchiya K, Shiba K, et al. A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition. Sci Rep. 2018;8(1):16113. doi:10.1038/s41598-018-34305-x
   PubMedGoogle Scholar
• Kim SR, Lee SG, Kim SH, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):2127. doi:10.1038/s41467-020-15983-6
   PubMed Web of Science ®Google Scholar
• de Souza P, da Silva LM, de Andrade SF, et al. Recent advances in the knowledge of naturally-derived bioactive compounds as modulating agents of the renin-angiotensin-aldosterone system: therapeutic benefits in cardiovascular diseases. Curr Pharm Des. 2019;25(6):670–684. doi:10.2174/1381612825666190329122443
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao M, Yu X, et al. Pharmacological modulation of vagal nerve activity in cardiovascular diseases. Neurosci Bull. 2019;35(1):156–166. doi:10.1007/s12264-018-0286-7
   PubMed Web of Science ®Google Scholar
• Shin SJ, Chung S, Kim SJ, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One. 2016;11(11):e0165703. doi:10.1371/journal.pone.0165703
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382(9896):941–950. doi:10.1016/S0140-6736(13)60683-2
   PubMed Web of Science ®Google Scholar
• Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13(2):119–126. doi:10.1177/1479164115616901
   PubMed Web of Science ®Google Scholar
• Basu D, Huggins LA, Scerbo D, et al. Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol. 2018;38(9):2207–2216. doi:10.1161/ATVBAHA.118.311339
   PubMed Web of Science ®Google Scholar
• Dimitriadis GK, Nasiri-Ansari N, Agrogiannis G, et al. Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice. Mol Cell Endocrinol. 2019;494:110487. doi:10.1016/j.mce.2019.110487
   PubMed Web of Science ®Google Scholar
• Ortega R, Collado A, Selles F, et al. SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice. Arterioscler Thromb Vasc Biol. 2019;39(8):1614–1628. doi:10.1161/ATVBAHA.119.312659
   PubMed Web of Science ®Google Scholar
• Pennig J, Scherrer P, Gissler MC, et al. Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice. Sci Rep. 2019;9(1):17937. doi:10.1038/s41598-019-54224-9
   PubMedGoogle Scholar
• Gragnano F, Calabro P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis. 2018;269:219–228. doi:10.1016/j.atherosclerosis.2018.01.012
   PubMed Web of Science ®Google Scholar
• Nakatsu Y, Kokubo H, Bumdelger B, et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipid-metabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice. Int J Mol Sci. 2017;18(8). doi:10.3390/ijms18081704
   Web of Science ®Google Scholar
• Han JH, Oh TJ, Lee G, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-/-) mice fed a western diet. Diabetologia. 2017;60(2):364–376. doi:10.1007/s00125-016-4158-2
   PubMed Web of Science ®Google Scholar
• Gaspari T, Spizzo I, Liu H, et al. Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: a potential mechanism for inhibition of atherogenesis. Diab Vasc Dis Res. 2018;15(1):64–73. doi:10.1177/1479164117733626
   PubMed Web of Science ®Google Scholar